No Patient Left Behind convenes stakeholders to promote a biotech social contract that ensures:
prescribed treatments authorized by an insurer have no or low out-of-pocket costs
drugs go generic without undue delay
sufficient incentives remain in place to promote continued innovation
Watch our presentations below.
Inflation Reduction Act (IRA) Game Theory: Impact on Biotech Builders and (how) can it be fixed?
September 20, 2022 - Experts from the innovator, investor, and health plan communities provide analysis for biotech leaders on the impacts of new IRA legislation. The moderators and panel detail the law's provisions and implementation timeline, its potential impact on R&D financings, likely health plan formulary changes, and expected disruption to new small molecule patient therapies.
Peter Kolchinsky, Managing Partner, RA Capital
Tess Cameron, Principal, RA Capital
Featured speakers included:
David Ricks, CEO, Lilly & Co.
Jake Klaisner, Consulting Actuary, Milliman
Alice Valder Curran, Partner, Hogan Lovells
Deborah Gan, Founder, North Star Access Consulting
Peter Rubin, Executive Director, NPLB
The good, bad, and ugly of the Inflation Reduction Act